CoChat

Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID

Open access
Garcia-Perez, Laura, van Eggermond, Marja, van Roon, Lieke, Vloemans, Sandra A., Cordes, Martijn, Schambach, Axel, Rothe, Michael, Berghuis, Dagmar, Lagresle-Peyrou, Chantal, Cavazzana, Marina, Zhang, Fang, Thrasher, Adrian J., Salvatori, Daniela, Meij, Pauline, Villa, Anna, Van Dongen, Jacques J.M., Zwaginga, Jaap-Jan, van der Burg, Mirjam, Gaspar, H. Bobby, Lankester, Arjan, Staal, Frank J.T., Pike-Overzet, Karin · 2020 · Molecular Therapy - Methods & Clinical Development
Cited by 56

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Recombinase-activating gene-1 (RAG1)-deficient severe combined immunodeficiency (SCID) patients lack B and T lymphocytes due to the inability to rearrange immunoglobulin and T cell receptor genes. Gene therapy is an alternative for those RAG1-SCID patients who lack a suitable bone marrow donor. We designed lentiviral vectors with different internal promoters driving codon-optimized RAG1 to ensure optimal expression. We used Rag1 −/− mice as a preclinical model for RAG1-SCID to assess the efficacy of the various vectors. We observed that B and T cell reconstitution directly correlated with RAG1 expression. Mice with low RAG1 expression showed poor immune reconstitution; however, higher expression resulted in phenotypic and functional lymphocyte reconstitution comparable to mice receiving wild-type stem cells. No signs of genotoxicity were found. Additionally, RAG1-SCID patient CD34 + cells transduced with our clinical RAG1 vector and transplanted into NSG mice led to improved human B and T cell development. Considering this efficacy outcome, together with favorable safety data, these results substantiate the need for a clinical trial for RAG1-SCID.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2020.03.016

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 56

Metadata

Authors
Garcia-Perez, L., van Eggermond, M., van Roon, L., Vloemans, S. A., Cordes, M., Schambach, A., Rothe, M., Berghuis, D., Lagresle-Peyrou, C., Cavazzana, M., Zhang, F., Thrasher, A. J., Salvatori, D., Meij, P., Villa, A., Van Dongen, J. J. M., Zwaginga, J.-J., van der Burg, M., Gaspar, H. B., Lankester, A., Staal, F. J. T., & Pike-Overzet, K.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2020-06
Volume
17
Pages
666-682
ISSN
2329-0501 (ISSN-L)
OpenAlex
W3014495642
Cited by
56
References
5
FWCI
4.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. https://app.cochat.ai/papers/10.1016/j.omtm.2020.03.016
The paper
Garcia-Perez, L., van Eggermond, M., van Roon, L., Vloemans, S. A., Cordes, M., Schambach, A., Rothe, M., Berghuis, D., Lagresle-Peyrou, C., Cavazzana, M., Zhang, F., Thrasher, A. J., Salvatori, D., Meij, P., Villa, A., Van Dongen, J. J. M., Zwaginga, J.-J., van der Burg, M., Gaspar, H. B., . . . Pike-Overzet, K. (2020). Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2020.03.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.